TrialCompass™ TCL
Back to results
RecruitingPriority 2 · High priorityNCT06067347

A Global Study of the PETAL Consortium

ClinicalTrials.gov

Plain-language summary

This study is evaluating a new treatment as a treatment for people newly diagnosed with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. It is available at 10 US locations across multiple states.

Who can join (key eligibility)

  • Age 18 Years or older
  • Newly diagnosed, not yet treated

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Drugs / treatments
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Global Study of the PETAL Consortium

NCT06067347

Status: Recruiting | Priority: High

Plain-language summary

This study is evaluating a new treatment as a treatment for people newly diagnosed with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. It is available at 10 US locations across multiple states.

Who can join

  • Age 18 Years or older
  • Newly diagnosed, not yet treated

What's being tested

Drugs / treatments:

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 1200 patients

Primary endpoint: Overall Survival; Progression-free Survival; Duration of Response; Time to progression; Number of subjects proceeding to stem cell transplantation; Association of tumor specific somatic variants with treatment response

Ages: 18 Years to —

Start date: 2024-01-05 | Est. completion: 2028-01

Locations

10 US sites · 14 total

California, Colorado, Florida, Massachusetts, Minnesota, New Jersey, Ohio, Pennsylvania, Virginia

Contact

Salvia Jain, MD | salvia.jain@mgh.harvard.edu | 650-224-0183

Sponsor: Massachusetts General Hospital (OTHER)

Tags

CTCL · ENKTL · Newly diagnosed · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06067347

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.